Bioscience veteran brings 35 years of health care industry experience to the Board

NXT-ID, Inc. NXTD today announced that Robert A. Curtis, Pharm.D., MBA, has joined its Board of Directors, effective July 25, 2018. Dr. Curtis, a 35-year veteran of the bioscience industry, will add a wealth of health care experience to the Board of Directors.

“Robert a long history of successfully bringing new heathcare technologies to market and a deep background within the industry,” said NXT-ID CEO Gino Pereira. “His expertise and insights will be particularly valuable to the Board as we develop and execute strategies to grow our healthcare offerings and expand the market opportunities for that division of our company.”

Dr. Curtis currently serves as a consultant to emerging technology companies and serves on the board or as an advisor to a number of private entrepreneurial companies. He recently served as the Executive Chairman and Director of the Trudeau Institute in Saranac Lake, NY, as well as Chief Executive Officer of the Regional Technology Development Corporation of Cape Cod, MA, where he was responsible for identifying and commercializing technology from the Marine Biological Laboratory and the Woods Hole Oceanographic Institute.

Dr. Curtis has been a Founder and CEO of several companies, including HistoRx, Inc., Cape Aquaculture Technologies, Inc., and Lion Pharmaceuticals/Phoenix Drug Discovery LLC. He assisted in the founding of Environmental Operating Solutions, Inc, which applied denitrification technology to wastewater with the company being sold in 2017. He was Co-founder of and CEO of CombiChem, Inc., which was purchased by Dupont Pharmaceuticals and served as founding President and CEO of MetaMorphix, Inc., a joint venture between Genetics Institute, Inc. and The Johns Hopkins School of Medicine.

Prior to these entrepreneurial endeavors, Dr. Curtis held senior management positions at Pharmacopeia, Inc., Cambridge Neuroscience, Inc., and Pfizer, Inc. He also served as an Assistant Professor of Pharmacy Practice at the University of Illinois Medical Center in Chicago. Dr. Curtis holds a Bachelor of Science in Pharmacy from Massachusetts College of Pharmacy, a Pharm.D. from University of Missouri, and a Master Business Administration from Columbia University

“I am very pleased to join such as talented Board and look forward to contributing to the strategic direction of the company,” said Curtis. “My goal will be working with the other Board members and management team to leverage NXT-ID’s healthcare and other capabilities to bring value for shareholders.”

NXT- ID, Inc.

NXT-ID, Inc. (NASDAQ: NXTD) provides a comprehensive platform of technology products and services that enable the Internet of Things (IoT). With extensive experience in access control, biometric and behavior-metric identity verification, security and privacy, encryption and data protection, payments, miniaturization and sensor technologies, NXT-ID develops and markets groundbreaking solutions for payment and IoT applications. Its industry-leading technology products and solutions include MobileBio®, a suite of biometric solutions that secure consumers’ mobile platforms, the Wocket™ , a next-generation smart wallet and the Flye, a digital credit card developed in collaboration with WorldVentures. NXT-ID includes three mobile and IoT-related subsidiaries: LogicMark, LLC, a manufacturer and distributor of non-monitored and monitored personal emergency response systems (“PERS”) sold through dealers/distributors and the United States Department of Veterans Affairs; Fit Pay, Inc., a proprietary technology platform that delivers end-to-end solutions to device manufacturers for contactless payment capabilities, credential management, authentication and other secure services within the IoT ecosystem, and 3D-ID LLC, which is engaged in biometric identification and authentication. Learn more about NXT-ID at www.nxt-id.com. NXT-ID Inc. Corporate Contact: [email protected]. FitPay® and the FitPay® Payment Platform are trademarks of Fit Pay, Inc.

In the interest of full disclosure, we call the reader’s attention to the fact that Equities.com, Inc. is compensated by the companies profiled in the Spotlight Companies section. The purpose of these profiles is to provide awareness of these companies to investors in the micro, small-cap and growth equity community and should not in any way be considered as a recommendation to buy, sell or hold these securities. Equities.com is not a registered broker dealer, investment advisor, financial analyst, investment banker or other investment professional. We are a publisher of original and third party news and information. All profiles are based on information that is available to the public. The information contained herein should not be considered to be complete and is not guaranteed by Equities.com to be free from misstatement or errors. The views expressed are our own and not intended to be the basis for any investment decision. Readers are reminded to do their own due diligence when researching any companies mentioned on this website. Always bear in mind that investing in early-stage companies is risky and you are encouraged to only invest an amount that you can afford to lose completely without any change in your lifestyle. Equities has been compensated with cash, common shares and/or warrants for market awareness services provided.